In a 78-year-old woman with pulmonary emboli on rivaroxaban and rheumatoid arthritis on methotrexate who developed a severe pruritic eczema-like rash after starting omeprazole (and pantoprazole), with negative pemphigoid antibodies and biopsy showing excoriation, what is the optimal management of this drug‑induced dermatitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Discontinue Methotrexate Immediately as the Primary Culprit

The most likely cause of this persistent, severe pruritic eczematous eruption is methotrexate, not the proton pump inhibitors, and it should be discontinued immediately. While PPI hypersensitivity is documented, the clinical picture—persistent rash despite switching through multiple acid suppressants (omeprazole → pantoprazole → famotidine), biopsy showing apoptosis, and temporal relationship with methotrexate initiation—strongly suggests methotrexate-induced cutaneous toxicity rather than PPI allergy.

Clinical Reasoning

Methotrexate is the most probable culprit because:

  • Severe skin reactions are a known methotrexate complication: The FDA label explicitly warns that "severe, occasionally fatal, skin reactions have been reported following single or multiple doses of methotrexate" and that "reactions have occurred within days of oral, intramuscular, intravenous, or intrathecal methotrexate administration" 1

  • The rash persisted through three different acid suppression agents: True PPI class hypersensitivity would be unusual to extend to H2-blockers like famotidine, which has a completely different chemical structure. The persistence despite switching from PPIs to famotidine argues strongly against PPI causation

  • Apoptosis on biopsy is characteristic of drug-induced interface dermatitis: This histologic finding is more consistent with methotrexate toxicity than typical PPI hypersensitivity reactions

  • Temporal relationship: The gastroscopy was 4 months ago, but the rash developed "soon after" starting rheumatoid arthritis treatment with methotrexate

PPI Hypersensitivity Context

While PPI-induced cutaneous reactions do occur, they typically present as:

  • DRESS syndrome (with eosinophilia, which is absent here) 2, 3, 4
  • Subacute cutaneous lupus erythematosus 5
  • Prurigo or acute generalized exanthematous pustulosis 6, 7

Cross-reactivity among PPIs is well-documented 5, 6, 4, but cross-reactivity between PPIs and H2-receptor antagonists (famotidine) is not established because they are structurally unrelated. The fact that the rash persisted after switching to famotidine essentially rules out PPI class hypersensitivity as the primary cause.

Management Algorithm

Immediate Actions:

  1. Discontinue methotrexate immediately - This is the highest priority intervention given the FDA warning about severe skin reactions 1

  2. Maintain famotidine for gastric protection (if still needed for the original indication from 4 months ago)

  3. Initiate systemic corticosteroids: Given the severity and persistence of symptoms:

    • Start prednisone 0.5-1 mg/kg/day orally
    • Taper over 4-6 weeks as symptoms improve
    • This approach is supported by management of severe drug-induced cutaneous reactions 8

  4. Add symptomatic management:

    • High-potency topical corticosteroids for localized lesions
    • Oral antihistamines (H1-blockers) for pruritus
    • Consider gabapentin 300-900 mg/day if antihistamines fail to control pruritus 8

Monitoring:

  • Clinical reassessment in 48-72 hours: Expect improvement within this timeframe if methotrexate is the culprit
  • Weekly follow-up during corticosteroid taper to monitor for flare
  • Complete blood count: Monitor for any hematologic toxicity from methotrexate

Rheumatoid Arthritis Management:

Coordinate with rheumatology immediately to transition to alternative DMARD therapy. According to EULAR 2025 guidelines, if methotrexate must be discontinued due to toxicity, options include 9:

  • Leflunomide or sulfasalazine as alternative conventional synthetic DMARDs
  • Biologic DMARDs (TNF inhibitors, abatacept, rituximab, IL-6 inhibitors)
  • JAK inhibitors (though consider cardiovascular risk factors given age and history of pulmonary emboli)

Critical Pitfalls to Avoid

  • Do not continue methotrexate while investigating: The FDA label emphasizes that recovery occurs with discontinuation, and delayed recognition can lead to severe outcomes 1

  • Do not assume PPI causation based solely on temporal proximity: The persistence through famotidine is the key discriminating feature

  • Do not rechallenge with methotrexate: Given the severity and persistence of this reaction, methotrexate should be permanently contraindicated

  • Do not forget anticoagulation management: Ensure rivaroxaban continues uninterrupted for pulmonary embolism history; there is no indication to discontinue it

Expected Outcome

If methotrexate is the culprit, expect significant improvement within 1-2 weeks of discontinuation with corticosteroid support. Complete resolution may take several weeks. If no improvement occurs within 2 weeks despite these interventions, reconsider the diagnosis and consider dermatology consultation for alternative etiologies.

References

8
Guideline

drug allergy: a 2022 practice parameter update.

Journal of Allergy and Clinical Immunology, 2022

Related Questions

Can alprazolam, cyclobenzaprine, pantoprazole, simvastatin, or vitamin B12 increase eosinophil count in blood work?
Can chronic use of proton-pump inhibitors (e.g., omeprazole, esomeprazole) cause scalp pruritus?
How should I evaluate and manage a patient with a blood pressure of 122/77 mm Hg and a heart rate of 123 beats per minute (tachycardia)?
Should a 13-year-old patient requesting breast augmentation undergo the procedure, and what is the appropriate management if it should not be performed?
In a 13‑day‑old infant presenting with fever and poor feeding, what interventions should emergency medical services (EMS) perform?
What are the indications, dosing schedule, and safety considerations for rivastigmine in adult patients?
What are the common causes of tremor in a transplant patient?
What does it mean when an arterial line requires damping?
What are the newest FDA‑approved medications for attention‑deficit/hyperactivity disorder, what level of evidence supports them, and what are the recommended dosing and usage guidelines?
Should a 52-year-old man with LDL cholesterol 3.03 mmol/L, HDL cholesterol 1.34 mmol/L, and lipoprotein(a) 172 nmol/L be started on a statin?
What medication and treatment adjustments should be made for a 36-year-old man with chronic depression, generalized anxiety disorder, post‑traumatic stress disorder, attention‑deficit/hyperactivity disorder, and panic attacks, who is currently taking venlafaxine, sertraline, aripiprazole, mirtazapine, lamotrigine, gabapentin, uses marijuana three to four times weekly, consumes six to ten alcoholic drinks per week, and continues to feel depressed, irritable, and anxious?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.